BIOCRYST PHARMACEUTICALS, INC. Cash and Restricted Cash
BIOCRYST PHARMACEUTICALS, INC. (BCRX) had Cash and Restricted Cash of $156.38 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-05
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $156.38M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $173.38M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $91.34M.
- 2025-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $89.92M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $156.38M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $173.38M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $91.34M 10-Q · filed 2026-08-05 |
| 2025-06-30 | $89.92M 10-Q · filed 2026-08-05 |
| 2025-03-31 | $106.88M 10-Q · filed 2026-05-06 |
| 2024-12-31 | $106.32M 10-Q · filed 2026-08-05 |
| 2023-12-31 | $112.45M 10-K · filed 2026-02-26 |
| 2022-12-31 | $306.24M 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |